Rahway: Merck, known as MSD outside of the United States and Canada, has announced the discontinuation of the clinical ...

The results come two months after Merck shared positive results from the phase 3 KEYNOTE-689 trial of Keytruda as a ...

Merck & Co., a global pharmaceutical leader, focuses on oncology, immunology, and vaccines. Click here to check out my ...

Merck, a leading science and technology company, highlighted latest research and improvements in clinical outcomes for multiple sclerosis (MS) at the fifth congress of the Middle East North Africa ...

Merck & Co – known as MSD outside of the US and Canada – and Ridgeback Biotherapeutics have initiated a late-stage study to ...

Merck, Sharp, and Dohme (MSD) has announced it is to build a state of the art life sciences R&D facility in London, creating around 950 jobs. Known as Merck & Co in the US, the company said the ...

Merck announces phase 3 KEYLYNK-001 trial meets primary endpoint of PFS in patients with advanced epithelial ovarian cancer: Rahway, New Jersey Tuesday, December 10, 2024, 18:00 H ...

Merck, known as MSD outside of the United ... global clinical development, Merck Research Laboratories. "We continue to pursue the most promising science with a focus on agents with the greatest ...

MSD has reported positive topline outcomes from the Phase III MK-3475A ... pembrolizumab compared to its IV counterpart. MSD Research Laboratories oncology, global clinical development head ...

Merck Announces Phase 3 KEYLYNK-001 Trial Met Primary Endpoint of Progression-Free Survival (PFS) in Patients With Advanced ...